| Literature DB >> 28198418 |
Kristiaan Wouters1,2, Katrien Gaens1,2, Mitchell Bijnen1,2, Kenneth Verboven3,4, Johan Jocken3, Suzan Wetzels1,2, Erwin Wijnands1,5, Dominique Hansen4, Marleen van Greevenbroek1,2, Adriaan Duijvestijn1,2, Erik A L Biessen1,5,6, Ellen E Blaak3, Coen D A Stehouwer1,2, Casper G Schalkwijk1,2.
Abstract
Immune cell accumulation in adipose tissue (AT) is associated with the development of AT inflammation, resulting in metabolic dysfunction. Circulating immune cell patterns may reflect immune cell accumulation in expanding AT. However, data linking human leukocytes in blood and AT is lacking. We investigated whether blood immune cell populations are associated with their counterparts in subcutaneous (scAT) or visceral AT (vAT). Flow cytometry was performed on blood, scAT and vAT from 16 lean and 29 obese men. Circulating natural killer (NK)-cells, classical monocytes and nonclassical monocytes were higher in obese individuals. vAT, but not scAT, of obese individuals contained more inflammatory CD11c+ "M1" macrophages and NK cells compared to lean individuals. Blood classical monocytes were associated with CD11c+ macrophages in vAT but not scAT. This association was unrelated to expression of the adhesion molecules CD11b and CD11c or of the chemokine receptor CX3CR1 on these monocytes. Other AT immune cells were not associated with their respective counterparts in blood. Finally, CD11c+ macrophages and CD4+ T-cells in vAT were associated with their counterparts in scAT. In conclusion, blood classical monocytes reflect CD11c+ macrophages in vAT.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28198418 PMCID: PMC5309742 DOI: 10.1038/srep42665
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline parameters.
| Lean Subjects | Obese Subjects | P-value | |
|---|---|---|---|
| Age (years) | 51.5 (47.5–58.5) | 49.0 (45.0–54.0) | 0.210 |
| BMI (kg/m2) | 23.7 (22.7–24.8) | 37.4 (36.1–39.4) | <0.001 |
| Waist-to-hip ratio | 0.98 (0.96–0.99) | 1.09 (1.06–1.11) | <0.001 |
| Plasma glucose (mM) | 5.6 (5.2–5.9) | 5.8 (5.5–7.2) | 0.014 |
| Serum Insulin (mU/L) | 6.7 (5.5–12.1) | 19.0 (15.0–29.5) | <0.001 |
| HOMA-IR | 1.71 (1.3–3.2) | 5.7 (3.6–8.3) | <0.001 |
| HbA1C (%) | 5.2 (5.1–5.5) | 6.0 (5.4–6.8) | <0.001 |
| Fat percentage (%) | 22.2 (19.8–27.9) | 36.2 (34.6–38.3) | <0.001 |
Table shows baseline parameters from lean and obese individuals included in this study. Data are presented as median (interquartile range). Differences between lean and obese individuals are analysed with an independent student t-test. *P-value < 0.05 is considered statistically significant.
Immune cell populations in blood.
| Lean Subjects | Obese Subjects | P-value | |
|---|---|---|---|
| WBC (×10 * 9/L) | 6.9 (6.3–9.5) | 6.6 (5.7–8.4) | 0.197 |
| Lymphocytes (×10 * 9/L) | 1.9 (1.6–2.3) | 1.8 (1.5–2.2) | 0.136 |
| Monocytes (×10 * 9/L) | 0.5 (0.4–0.7) | 0.5 (0.4–0.6) | 0.416 |
| Basophils (×10 * 9/L) | 0.05 (0.04–0.07) | 0.04 (0.02–0.05) | 0.060 |
| Eosinophils (×10 * 9/L) | 0.22 (0.16–0.37) | 0.15 (0.08–0.26) | 0.065 |
| Neutrophils (×10 * 9/L) | 4.3 (3.0–6.0) | 3.7 (3.2–5.4) | 0.533 |
| B-cell (% of total) | 3.5 (2.0–5.0) | 3.7 (2.7–4.7) | 0.786 |
| T-cell (% of total) | 58.5 (55.2–62.8) | 52.8 (46.4–60.3) | 0.371 |
| CD4+ (% of total) | 13.5 (10.5–18.8) | 16.1 (12.1–18.6) | 0.304 |
| CD8+ (% of total) | 5.0 (2.9–10.2) | 6.5 (4.0–11.4) | 0.295 |
| T-helper (% of total) | 11.8 (9.5–16.7) | 14.9 (11.0–16.9) | 0.286 |
| T-regulatory (% of total) | 1.4 (1.0–1.8) | 1.4 (0.9–1.8) | 0.856 |
| NK-cells (% of total) | 2.9 (1.8–4.7) | 4.9 (3.1–6.5) | 0.016 |
| Classical Mono (% of total) | 4.6 (3.8–5.7) | 6.5 (4.6–7.5) | 0.012 |
| CD11c (MFI) (×103) | 5.1 (4.1–5.9) | 6.3 (4.8–7.4) | 0.242 |
| CD11b (MFI) (×103) | 20.5 (17.9–25.0) | 27.8 (24.6–31.3) | 0.008 |
| CX3CR1 (MFI) (×103) | 4.6 (3.8–5.5) | 5.4 (4.1–6.6) | 0.097 |
| Intermediate Mono (% of total) | 0.2 (0.2–0.3) | 0.3 (0.2–0.5) | 0.077 |
| CD11c (MFI) (×103) | 17.4 (16.0–19.1) | 17.4 (16.3–21.2) | 0.803 |
| CD11b (MFI) (×103) | 23.2 (20.7–30.6) | 30.7 (26.8–35.7) | 0.022 |
| CX3CR1 (MFI) (×103) | 12.7 (9.7–15.8) | 14.2 (11.9–16.0) | 0.153 |
| Nonclassical Mono (% of total) | 0.5 (0.4–0.8) | 1.0 (0.7–1.6) | 0.000 |
| CD11c (MFI) (×103) | 12.2 (9.8–13.5) | 15.1 (12.8–16.8) | 0.098 |
| CD11b (MFI) (×103) | 5.3 (3.2–6.6) | 6.5 (4.7–7.3) | 0.066 |
| CX3CR1 (MFI) (×103) | 10.7 (8.7–12.7) | 12.0 (10.4–13.7) | 0.043 |
Blood cells were either measured by an automated clinical assay (×109 cells/L) or with flow cytometry (% of total cells) in whole blood. Data are presented as median (interquartile range). Differences in immune cell populations were analysed with linear regression with adjustment for age. *P-value < 0.05 is considered significant.
Immune cell populations in scAT and vAT.
| Lean Subjects | Obese Subjects | P-value | ||
|---|---|---|---|---|
| CD45+ (% of total) | 48.3 (36.6–54.1) | 38.4 (30.2–50.6) | 0.571 | |
| CD11c− CD11b+ (% of total) | 3.8 (0.9–7.2) | 2.6 (1.7–5.1) | 0.873 | |
| CD11c+ CD11b+ (% of total) | 5.6 (2.3–9.5) | 6.9 (4.2–11.1) | 0.587 | |
| NK-cells (% of total) | 3.0 (2.2–4.0) | 3.1 (2.4–4.9) | 0.971 | |
| T-cells (% of total) | 24.4 (18.7–33.0) | 24.7 (21.4–27.6) | 0.971 | |
| T-helper cells (% of total) | 14.0 (9.5–20.6) | 11.2 (8.9–14.8) | 0.583 | |
| Cytotoxic T-cells (% of total | 7.6 (5.6–9.6) | 8.7 (6.0–10.4) | 0.375 | |
| B-cells (% of total) | 0.7 (0.4–1.0) | 0.7 (0.5–1.5) | 0.862 | |
| CD45+ (% of total) | 41.9 (25.6–47.5) | 55.7 (50.6–61.6) | <0.001 | |
| CD11c− CD11b+ (% of total) | 4 (1.4–4.5) | 5.0 (3.6–7.8) | 0.066 | |
| CD11c+ CD11b+ (% of total) | 2.3 (1.5–3.5) | 5.8 (2.3–8.2) | 0.009 | |
| NK-cells (% of total) | 2.7 (1.6–4.1) | 3.8 (2.7–5.8) | 0.029 | |
| T-cells (% of total) | 27.3 (15.5–40,6) | 40.8 (24.1–46.2) | 0.107 | |
| T-helper cells (% of total) | 12.9 (9.8–25.1) | 16.6 (12.4–25.2) | 0.786 | |
| Cytotoxic T-cells (% of total) | 8.8 (6.1–16.5) | 14.8 (6.7–21.8) | 0.173 | |
| B-cells (% of total) | 0.5 (0.2–3.3) | 1.4 (0.9–2.2) | 0.055 |
Immune cells were measured with flow cytometry in SVF from scAT and vAT biopsies. Data (% of total cells) are presented as median (interquartile range). Differences in immune cell populations were analysed with linear regression with adjustment for age. *P-value < 0.05 is considered significant.
Figure 1Leukocytes in vAT (represented as % of stromal vascular cells on the Y-axis) were associated with circulating monocyte subsets (represented as % of leukocytes on the X-axis) and with scAT leukocytes (represented as % of stromal vascular cells on the X-axis).
Squares represent data of lean individuals and open circles represent data from obese individuals. Regression analyses are shown for CD11c+ CD11b+ M1 macrophages with (A) classical monocytes (β = 0.67, p = 0.014), (B) intermediate monocytes (β = 2.61, p = 0.40) and (C) nonclassical monocytes (β = 1.90, p = 0.054) and for CD11c−CD11b+ M2 macrophages in vAT with circulating (D) classical monocytes (β = −0.023, p = 0.95), (E) intermediate monocytes (β = −5.54, p = 0.20) and (F) nonclassical monocytes (β = 0.41, p = 0.77).
Figure 2Regression analyses between scAT and vAT are shown for (A) CD11c+ CD11b+ M1 macrophages (β = 0.36, p < 0.001), (B) CD11c−CD11b+ M2 macrophages (β = 0.26, p = 0.12), (C) CD4+ Th cells (β = 0.61, p = 0.006), (D) CD8+ Tc cells (β = 0.33, p = 0.55), (E) B-cells (β = −0.64, p = 0.31), and (F) NK cells (β = 0.15, p = 0.45).